Bullish & Foolish
Full ZBIO fundamentals All 466 on the Survival Watch

ZBIOZenas BioPharma, Inc.

Is Zenas BioPharma struggling financially?

Yes, by its own account. Zenas BioPharma told the SEC on 31 Mar 2026, in Form 8-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Regulatory win

    Such designations include fast track designation, breakthrough therapy designation, and priority review designation. We intend to seek priority review designation for obexelimab for IgG4-RD.

    Form 10-K, filed 16 Mar 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$2.1B
Source filing
8-K 31 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

38+ mo

Runs out some time after Aug 2029, raising nothing.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$643.1M

÷

Cash burned over the last 12 months

$172.4M

What Zenas BioPharma told the SEC

…recruit additional management or clinical and scientific personnel; the fact that the Company’s independent registered public accounting firm has expressed substantial doubt about the Company’s ability to continue as a going concern in its report on the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025; the Company’s ability to grow the…

Zenas BioPharma, Inc., Form 8-K, filed 31 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 42.0% share-count increase The company issued stock. Each share now owns 29.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 37% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt